Santa Farma Pharmaceuticals, one of Türkiye’s long-established domestic pharmaceutical companies, has broadened its strategic partnership with MEALIS Middle East Life Sciences. Under the newly signed agreement, the sales, marketing, and distribution rights of the iron sucrose complex product, which is licensed and manufactured by Santa Farma, have been transferred to MEALIS, effective December 11, 2025.
Santa Farma highlighted its manufacturing capabilities, noting that its production facility located in the GEBKİM Organized Industrial Zone in Dilovası was established with an investment of €150 million. Commissioned in 2015, the site spans a total area of 80,000 square meters, including 44,000 square meters of indoor space, and has a single-shift annual production capacity of 150 million boxes. The facility holds EU-GMP, TR-GMP, and Jordan GMP certifications and not only manufactures Santa Farma products for Türkiye and export markets but also supports localization efforts for global and domestic pharmaceutical companies that import products from abroad.
MEALIS, which operates under the principle of promoting healthy living at every age, began its activities in Dubai and Beirut in 2013 and launched its Türkiye operations in 2014. The company is active in 35 countries, including Türkiye, across Eastern Europe, the Middle East, and North Africa, with a portfolio spanning pharmaceuticals, medical devices, and dietary supplements. In Türkiye, MEALIS focuses on the promotion, marketing, sales, and distribution of both pharmaceutical and non-pharmaceutical products.
With the expanded agreement, the two companies aim to enhance market access for the iron sucrose complex product and manage sales and distribution more effectively through MEALIS’s regional network.
